NRAS XL StripAssay covers 22 mutations in exon 2 (codons 12/13), exon 3 (codons 59/60/61) and exon 4 (codon 146), and thus will allow to analyze all three critical NRAS exons according to current guidelines from various pathology societies and pharmaceutical companies.
The effectiveness of the anti-EGFR monoclonal antibodies cetuximab (Erbitux) and panitumumab (Vectibix) is very well established in KRAS non-mutated colorectal cancer (CRC) patients. Patients that harbour KRAS mutations, on the other hand, have been found to be resistant to those therapies. NRAS, another member of the ras gene family, is also mutated in CRC and various other tumors. Recently the PRIME Study showed that not only KRAS, but also NRAS mutations, will predict a lack of response to panitumumab. AMGEN, the manufacturer of Vectibix, meanwhile released a safety note recommending NRAS testing before starting panitumumab therapy.